Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

Insulet Corporation (PODD) CEO Shacey Petrovic on Q4 2020 Results - Earnings Call Transcript

Shares of Insulet (NASDAQ:PODD) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 425.00% year over year to ($0.26), which missed the estimate of ($0.04).

Recap: Insulet Q4 Earnings

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2020. Full Year Financial Highlights: Full Year 2020 revenue of $904.4 million, up 22.5%, or 21.9% in constant currency1, compared to $738.2 million in the prior year, exceeds guidance of 20% to 21% on a

Insulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year

Biogen

Bio-Rad Laboratories

CVS Health

Horizon Pharma

Moderna

QuidelOrtho Corp

Teladoc

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Top Healthcare Stocks for February 2021

Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.

Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the launch of the Omnipod DASH® Insulin Management System (Omnipod DASH System) in Canada. “We're thrilled to bring this convenient and easy-to-use insulin delivery system to Canada,” said Bret Christensen, Chief Commercial Officer of Insulet. “The Omnipod DASH System's slee

Insulet's Omnipod DASH® System Now Available in Canada

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2020 on February 23, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the

Insulet to Announce Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021

AGCO

Brandywine Realty

Brookfield Property REIT

Enphase Energy

Fastly

HD Supply Hlds

NortonLifeLock

NRG Energy

Rockwell Automation

Tesla

Unum

Zoom Video

These are the stocks with the best value, fastest growth, and most momentum for January.

Top Stocks for January 2021

Acceleron Pharma

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Top Healthcare Stocks for January 2021

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021 at 9:10 a.m. (Eastern Time) To listen to the live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the audio webcast will also be available following the ev

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Insulet (PODD) Down 0.1% Since Last Earnings Report: Can It Rebound?

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Top Healthcare Stocks for December 2020

Align Technology

Repligen

ResMed

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

Insulet's (PODD) CEO Shacey Petrovic on Q3 2020 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Beats Q3 Earnings and Revenue Estimates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended September 30, 2020. Third Quarter Financial Highlights: Third quarter 2020 revenue of $234.0 million, up 21.8%, or 19.9% in constant currency1, compared to $192.1 million in the prior year, exceeds guidance of 13% to 15% on a cons

Insulet Reports Third Quarter 2020 Revenue Increase of 22% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced special activities to support its ongoing commitment to diabetes awareness during the month of November. Approximately 463 million people live with diabetes worldwide and that number is expected to grow to nearly 700 million by 20451. Insulet turns November into “YESvember”

Insulet Raises Awareness for Diabetes Throughout November

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is being honored by two Massachusetts agencies for the Company's contributions relating to COVID-19 and its sustainable manufacturing practices. MassEcon, the state's private sector partner in promoting business growth in Massachusetts, has named Insulet one of 10 recipie

Insulet Recognized as Global Impact Corporate Hero and Manufacturer of the Year

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Insulet (PODD) Q3 Earnings Expected to Decline

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Insulet Corporation (NASDAQ:PODD)? The smart money sentiment can provide an answer to this question.

Were Hedge Funds Right About Embracing Insulet Corporation (PODD)?

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Wayne A. I. Frederick, M.D., has been appointed to the Company's Board of Directors, effective immediately. He will also serve on the Board's Audit Committee. Dr. Frederick is the president of Howard University and serves as the Charles R. Drew Endowed Chair of Surgery

Insulet Appoints Wayne A. I. Frederick, M.D.

Copart

Entegris

Intuit

This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.

Nasdaq Set to Outperform 2019 on Digitization Push: 5 Picks

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2020 on November 4, 2020 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the I

News for Insulet Stock (PODD)